Literature DB >> 7875477

Effect of three laxatives and a cation exchange resin on fecal sodium and potassium excretion.

M Emmett1, R E Hootkins, K D Fine, C A Santa Ana, J L Porter, J S Fordtran.   

Abstract

BACKGROUND/AIMS: The treatment of hyperkalemia in patients with renal insufficiency often includes the ingestion of sorbitol and a cation exchange resin. Sorbitol alone may be used to remove sodium and water from overloaded patients. The efficacy of these regimens has never been compared with other laxative or laxative-resin combinations. The aim of the study was to compare the relative effect of three laxatives with different mechanisms of action, alone and in combination with resin, on fecal sodium and potassium excretion.
METHODS: Sodium, potassium, and water excretion in 12-hour stool collections were analyzed after various laxative-resin combinations in normal subjects.
RESULTS: Correctol (yellow phenolphthalein) (Schering Plough Health Care Products, Memphis, TN) was more effective than sorbitol or sodium sulfate in causing fecal sodium and potassium loss. Resin recovery in stool was much greater with phenolphthalein than with other laxatives, and more potassium was excreted in stool with phenolphthalein-resin than with phenolphthalein alone or other laxative-resin combinations. Sorbitol caused more undesirable gastrointestinal symptoms than did sodium sulfate or phenolphthalein.
CONCLUSIONS: In normal people, phenolphthalein (1) is preferable to other laxatives in causing fecal sodium and potassium excretion, (2) hastens resin transit through the intestine compared with other laxatives, and (3) produces greater fecal potassium excretion when combined with resin than phenolphthalein alone or other laxative-resin combinations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7875477     DOI: 10.1016/0016-5085(95)90448-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  17 in total

1.  [Hyperkalemia : what can we expect from new potassium-lowering drugs?].

Authors:  R Schmitt
Journal:  Internist (Berl)       Date:  2015-07       Impact factor: 0.743

2.  Runner's new diet, his collapse, and his ECG: when a rapid ECG diagnosis can save the day.

Authors:  Melissa Ringer; Simon Pulfrey
Journal:  Can Fam Physician       Date:  2014-04       Impact factor: 3.275

3.  Taking a Second Look at Kayexalate.

Authors:  Dennis J Malone
Journal:  Hosp Pharm       Date:  2015-11-24

Review 4.  Updates in hyperkalemia: Outcomes and therapeutic strategies.

Authors:  Csaba P Kovesdy
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

5.  A physiologic-based approach to the treatment of acute hyperkalemia.

Authors:  Roman Shingarev; Michael Allon
Journal:  Am J Kidney Dis       Date:  2010-06-08       Impact factor: 8.860

Review 6.  Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia.

Authors:  Calvin J Meaney; Mario V Beccari; Yang Yang; Jiwei Zhao
Journal:  Pharmacotherapy       Date:  2017-03-10       Impact factor: 4.705

7.  Effectiveness of Sodium Polystyrene Sulfonate for Short-Term Treatment of Hyperkalemia.

Authors:  Josh Batterink; Jane Lin; Sarah Hin Mui Au-Yeung; Tara Cessford
Journal:  Can J Hosp Pharm       Date:  2015 Jul-Aug

8.  Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol.

Authors:  C E McGowan; S Saha; G Chu; M B Resnick; S F Moss
Journal:  South Med J       Date:  2009-05       Impact factor: 0.954

9.  Potassium-Binding Agents for the Clinical Management of Hyperkalemia.

Authors:  Martin Chaitman; Deepali Dixit; Mary Barna Bridgeman
Journal:  P T       Date:  2016-01

Review 10.  Management of hyperkalaemia in chronic kidney disease.

Authors:  Csaba P Kovesdy
Journal:  Nat Rev Nephrol       Date:  2014-09-16       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.